Company Overview and News

3
What's in Store for Cerner (CERN) This Earnings Season?

2018-10-16 zacks
Our experts cut down 220 Zacks Rank #1 Strong Buys to the 7 most likely to jump in price immediately.
CERN

5
Cerner's Millennium Platform Integrated at McLaren Hospital

2018-10-12 zacks
Cerner Corporation’s (CERN - Free Report) coveted Cerner Millennium electronic health record (EHR) platform has been recently integrated with B. Braun Medical’s Infusomat Space Large Volume Pumps at the McLaren Greater Lansing Hospital, Michigan. Notably, this will help reduce medication administration errors through the use of real-time data.
CBSH MDRX CBSHP CERN BAX ATHN CBCB

5
Here's Why You Should Hold on to athenahealth (ATHN) for Now

2018-10-11 zacks
athenahealth, Inc. (ATHN - Free Report) has topped estimates in the trailing four quarters. For the quarters ahead, the company is expected to gain from its solid focus on cloud-based services and a raised guidance for 2018. However, cutthroat competition might pose a threat.
MDRX CERN ISRG ATHN

3
Cerner to Release Third Quarter 2018 Earnings Results October 25

2018-10-11 globenewswire
KANSAS CITY, Mo., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Cerner Corporation (Nasdaq: CERN) today announced it will release its third quarter 2018 earnings results after the market closes Thursday, Oct. 25. Following the release, the company will hold a conference call at 3:30 p.m. CT that can be accessed via dial-in or webcast. On the call, Cerner will discuss its results and outlook and answer questions from the investment community.
CERN

3
Allscripts (MDRX) & Appriss Health Collaborate to Fight SUD

2018-10-09 zacks
Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) recently announced a partnership with Appriss Health to enable point-of-care access to prescription drug monitoring program (PDMP). The integration will be done through Appriss Health’s PMP Gateway platform with a view to reduce deaths from substance use disorder (SUD).
MDRX CERN VEEV ISRG

9
Here's Why You Should Hold on to Cerner (CERN) Stock for Now

2018-10-05 zacks
Cerner Corporation (CERN - Free Report) is expected to gain from its solid focus on big-data based services and a slew of developments. However, the company operates in an intensely competitive industry.
MDRX CERN VEEV ATHN YY

5
Veeva's Technology Partner Joins Verix to Boost CRM Platform

2018-10-02 zacks
Veeva Systems Inc.’s (VEEV - Free Report) Technology Partner Program recently collaborated with Verix to integrate insights and suggestions into the Veeva CRM (Customer Relationship Management) platform, based on its AI (Artificial Intelligence)-driven analytical engine. Notably, this will help Veeva CRM boost its performance and fortify Veeva Systems’ foothold in cloud-based services in the healthcare space.
CERN VEEV HMSY NR ATHN

12
Here's Why You Should Hold on to Allscripts (MDRX) Stock Now

2018-09-27 zacks
With a market capitalization of approximately $2.51 billion, Allscripts Healthcare Solutions Inc. (MDRX - Free Report) is likely to gain from higher adoption of Electronic Health Record (EHR) solutions, particularly the Sunrise EHR platform. However, intense competition in the MedTech space is a headwind.
MDRX NBL CERN MCK ATHN

7
Cerner CommunityWorks Selected by Pershing Health System

2018-09-27 zacks
Cerner Corporation’s (CERN - Free Report) coveted CommunityWorks was recently selected by Pershing Health System to implement its electronic health record (“EHR") and revenue cycle management solutions (“RCM”). Pershing Health System, a 25-bed Critical Access Hospital located in Brookfield, MO, will receive health IT solutions from Cerner to support rural community health care organizations.
MASI NBL CERN VEEV ATHN

10
NextGen Rides on Prospects in RCM Space, Competition Rife

2018-09-25 zacks
On Sep 24, we issued an updated research report on NextGen Healthcare, Inc. (NXGN - Free Report) . Solid demand for Revenue Cycle Management (RCM) solutions is likely to provide NextGen with a competitive edge in the MedTech space. However, cutthroat competition in the healthcare information systems and services market is a headwind.
CERN MCK QSII ATHN NXGN

5
Cerner's CommunityWorks Picked by Reeves County Hospital

2018-09-21 zacks
Cerner Corporation’s (CERN - Free Report) coveted CommunityWorks was recently selected by Reeves County Hospital District. Cerner’s electronic health record (EHR) and revenue cycle solutions will be implemented across the 25-bed critical access hospital to improve quality of health care in Reeves and also in adjacent West Texas communities.
MASI CERN ISRG ATHN

5
Cerner Integrated Platform Implemented by Spectrum Health

2018-09-20 zacks
Cerner Corporation (CERN - Free Report) recently announced that Spectrum Health & Human Services has implemented an electronic health record (EHR) and revenue cycle solution through the Cerner Integrated – Community Behavioral Health cloud technology to treat psychological disorders.
CERN VEEV ISRG LB ATHN

5
Veeva's Vault CDMS to Unify Clinical Data in Single Platform

2018-09-19 zacks
Veeva Systems Inc. (VEEV - Free Report) recently announced that its next-generation cloud single clinical data management application, Veeva Vault CDMS, eliminates the need for multiple tools and helps streamline clinical data. Thus, healthcare companies can now get a complete view of clinical data in a single application and move away from a complex combination of data.
CERN VEEV ISRG ATHN

5
Veeva Gains as MD&D Companies Pick Its Cloud-Based Services

2018-09-14 zacks
Shares of Veeva Systems Inc. (VEEV - Free Report) rose 0.7% to $105.31 on continued adoption of the flagship Veeva Vault platform by medical device and diagnostics (MD&D) companies. Management announced that Veeva has more than 65 MD&D customers using Veeva Vault, including 11 of the world’s top 25 medical device companies.
CY CERN VEEV ISRG ATHN

3
CERN / Cerner Corp. 8-K (Current Report)

2018-09-10 sec.gov
Document UNITED STATES
CERN

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CERN / Cerner Corp. on message board site Silicon Investor.

Bank loans - is there a reason to be concerned? Bank loans - is there a reason to be concerned? Bank loans - is there a reason to be concerned? DTCC Concern DTCC Concern DTCC Concern
DTCC Concern DTCC Concern DTCC Concern new CA travel approval policy raises concerns new CA travel approval policy raises concerns new CA travel approval policy raises concerns
Cerner-Is this stock ready to break out soon! Cerner-Is this stock ready to break out soon! Cerner-Is this stock ready to break out soon! CERN -- a player in the health-care infor. industry CERN -- a player in the health-care infor. industry CERN -- a player in the health-care infor. industry
CERN - Cerner Corp. CERN - Cerner Corp. CERN - Cerner Corp. Active Traders: Level II Questions u0026 Concerns Active Traders: Level II Questions u0026 Concerns Active Traders: Level II Questions u0026 Concerns
Online Forum for Concerned Parents Online Forum for Concerned Parents Online Forum for Concerned Parents ANTHRAX Are you concerned about this fatal disease ANTHRAX Are you concerned about this fatal disease ANTHRAX Are you concerned about this fatal disease
CUSIP: 156782104